Pre-Emptive Treatment of Lidocaine Attenuates Neuropathic Pain and Reduces Pain-Related Biochemical Markers in the Rat Cuneate Nucleus in Median Nerve Chronic Constriction Injury Model

<table>Photomicrographs showing c-Fos-LI cells in the middle region of the CN ipsilateral to electrical stimulation four weeks after chronic constriction injury in control (a), presaline (b), pre-1% lido (c) and pre-5% lido (d) groups. Bar = 100 <i>μ</i>m.</table>

Anesthesiology Research and Practice

fig6

Figure 6

Figure 6: Pre-Emptive Treatment of Lidocaine Attenuates Neuropathic Pain and Reduces Pain-Related Biochemical Markers in the Rat Cuneate Nucleus in Median Nerve Chronic Constriction Injury Model 

Figure 6 | Pre-Emptive Treatment of Lidocaine Attenuates Neuropathic Pain and Reduces Pain-Related Biochemical Markers in the Rat Cuneate Nucleus in Median Nerve Chronic Constriction Injury Model 